Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Di Maio

Showing results (251-260 of 418) with videos related to

Pageof 42
Sort By:
Lung Cancer (Amsterdam, Netherlands)|August 22, 2013
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)M Neil Reaume, Natasha B Leighl, Nicole Mittmann, et al.
JCO Oncology Practice|January 11, 2024
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care SystemFrancesco Sparano, Johannes M Giesinger, Gianluca Gaidano, et al.
Breast (Edinburgh, Scotland)|October 2, 2023
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA studyMassimo Di Maio, Claudia Bighin, Francesco Schettini, et al.
BMC Cancer|March 26, 2005
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceErmelinda De Maio, Adriano Gravina, Carmen Pacilio, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)Giuseppe Maglietta, Angela Damato, Silvia Finotto, et al.
JAMA Network Open|February 23, 2023
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint InhibitorsDaniel A Goldstein, Gary M Ginsberg, Dorit Hofnung-Gabbay, et al.
Critical Reviews in Oncology/Hematology|March 6, 2021
Second medical opinion in oncological settingMarco Maruzzo, Nicla La Verde, Antonio Russo, et al.
Breast (Edinburgh, Scotland)|November 13, 2016
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysisMarta Bonotto, Lorenzo Gerratana, Massimo Di Maio, et al.
EMBO Reports|February 27, 2024
A neuroligin-2-YAP axis regulates progression of pancreatic intraepithelial neoplasiaEmanuele Middonti, Elena Astanina, Edoardo Vallariello, et al.
BMJ Open|September 11, 2019
Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocolSilvia Riva, Jane Bryce, Francesco De Lorenzo, et al.
Pageof 42

Showing results (251-260 of 418) with videos related to

Sort By:
Pageof 42
Lung Cancer (Amsterdam, Netherlands)|August 22, 2013
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)M Neil Reaume, Natasha B Leighl, Nicole Mittmann, et al.
JCO Oncology Practice|January 11, 2024
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care SystemFrancesco Sparano, Johannes M Giesinger, Gianluca Gaidano, et al.
Breast (Edinburgh, Scotland)|October 2, 2023
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA studyMassimo Di Maio, Claudia Bighin, Francesco Schettini, et al.
BMC Cancer|March 26, 2005
Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experienceErmelinda De Maio, Adriano Gravina, Carmen Pacilio, et al.
European Journal of Cancer (Oxford, England : 1990)|February 19, 2025
Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018)Giuseppe Maglietta, Angela Damato, Silvia Finotto, et al.
JAMA Network Open|February 23, 2023
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint InhibitorsDaniel A Goldstein, Gary M Ginsberg, Dorit Hofnung-Gabbay, et al.
Critical Reviews in Oncology/Hematology|March 6, 2021
Second medical opinion in oncological settingMarco Maruzzo, Nicla La Verde, Antonio Russo, et al.
Breast (Edinburgh, Scotland)|November 13, 2016
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysisMarta Bonotto, Lorenzo Gerratana, Massimo Di Maio, et al.
EMBO Reports|February 27, 2024
A neuroligin-2-YAP axis regulates progression of pancreatic intraepithelial neoplasiaEmanuele Middonti, Elena Astanina, Edoardo Vallariello, et al.
BMJ Open|September 11, 2019
Development and validation of a patient-reported outcome tool to assess cancer-related financial toxicity in Italy: a protocolSilvia Riva, Jane Bryce, Francesco De Lorenzo, et al.
Pageof 42